Literature DB >> 2645824

Central effects of drugs used in migraine prophylaxis evaluated by visual evoked potentials.

H C Diener1, E Scholz, J Dichgans, W D Gerber, A Jäck, A Bille, U Niederberger.   

Abstract

The present study used recordings of visual potentials evoked by pattern reversal (VEPs) to investigate the central effects of three drugs used in migraine prophylaxis: the calcium channel blocker nifedipine, the beta-1-selective blocker metoprolol, and the nonselective beta adrenoreceptor blocker propranolol. The study involved 58 patients with common or classical migraine who were treated in a double-blind randomized study over a period of 7 months, while the effectiveness of prophylactic treatment was recorded in headache diaries that were subjected to time series analysis. VEPs were recorded at the beginning of a 2-month baseline period without treatment, after 4 months of treatment, and at the end of a 3-month washout period. At baseline, migraine patients had significantly higher VEP amplitudes and longer latencies than did a group of 87 healthy control subjects. Patients were separated by statistical analysis into responders and nonresponders to each prophylactic treatment. Nifedipine had no effects on the frequency, intensity, and duration of migraine attacks, nor on amplitude and latency of the VEPs. In contrast, the use of beta blockers resulted in a significant decrease in VEP amplitude, both in responders and nonresponders, whereas VEP latency remained unchanged. VEP amplitudes returned to the initial values at follow-up in the nonresponders, but stayed at lower levels in responders. Beta blockers thus appear to have a significant effect on the increased excitability of the visual system in patients with migraine, although their action is not directly related to their reduction of migraine frequency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645824     DOI: 10.1002/ana.410250204

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

1.  Spatial frequency differentially affects habituation in migraineurs: a steady-state visual-evoked potential study.

Authors:  Koichi Shibata; Kiyomi Yamane; Yoshiko Nishimura; Hiromi Kondo; Kuniaki Otuka
Journal:  Doc Ophthalmol       Date:  2011-07-19       Impact factor: 2.379

Review 2.  Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Authors:  Till Sprenger; M Viana; C Tassorelli
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

3.  Prophylactic Therapy for Migraine.

Authors:  Shazia Afridi; Holger Kaube
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

Review 4.  Primary visual cortex excitability in migraine: a systematic review with meta-analysis.

Authors:  Francesco Brigo; Monica Storti; Frediano Tezzon; Paolo Manganotti; Raffaele Nardone
Journal:  Neurol Sci       Date:  2012-12-22       Impact factor: 3.307

5.  Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation.

Authors:  Marcus Gerwig; L Niehaus; P Stude; Z Katsarava; H C Diener
Journal:  J Headache Pain       Date:  2011-11-17       Impact factor: 7.277

Review 6.  Transcranial magnetic stimulation of visual cortex in migraine patients: a systematic review with meta-analysis.

Authors:  Francesco Brigo; Monica Storti; Raffaele Nardone; Antonio Fiaschi; Luigi Giuseppe Bongiovanni; Frediano Tezzon; Paolo Manganotti
Journal:  J Headache Pain       Date:  2012-04-27       Impact factor: 7.277

7.  Interictal brain activity differs in migraine with and without aura: resting state fMRI study.

Authors:  Péter Faragó; Bernadett Tuka; Eszter Tóth; Nikoletta Szabó; András Király; Gergő Csete; Délia Szok; János Tajti; Árpád Párdutz; László Vécsei; Zsigmond Tamás Kincses
Journal:  J Headache Pain       Date:  2017-01-25       Impact factor: 7.277

8.  The enigma of site of action of migraine preventives: no effect of metoprolol on trigeminal pain processing in patients and healthy controls.

Authors:  Julia M Hebestreit; Arne May
Journal:  J Headache Pain       Date:  2017-12-19       Impact factor: 7.277

9.  Methylprednisolone blocks interleukin 1 beta induced calcitonin gene related peptide release in trigeminal ganglia cells.

Authors:  Lars Neeb; Peter Hellen; Jan Hoffmann; Ulrich Dirnagl; Uwe Reuter
Journal:  J Headache Pain       Date:  2016-03-01       Impact factor: 7.277

10.  Brain Correlates of Single Trial Visual Evoked Potentials in Migraine: More Than Meets the Eye.

Authors:  Marco Lisicki; Kevin D'Ostilio; Gianluca Coppola; Alain Maertens de Noordhout; Vincenzo Parisi; Jean Schoenen; Delphine Magis
Journal:  Front Neurol       Date:  2018-05-30       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.